effective model for inducing nausea without vomiting can be used to study effects of nausea on GI function together with correlations with objective physiological and brain activity markers. The markers identified may help to reduce and refine animal experiments.

Competing interests None declared.

### PWE-052 PHENOTYPING THE EARLY MORNING RUSH (EMR) IN PATIENTS WITH DIARRHOEA PREDOMINANT IRRITABLE BOWEL SYNDROME (IBS-D)

doi:10.1136/gutjnl-2012-302514d.52

<sup>1</sup>K Garsed,\* <sup>2</sup>M Hastings, <sup>1</sup>C Lam, <sup>2</sup>P Whorwell, <sup>1</sup>R Spiller. <sup>1</sup>Nottingham Digestive Diseases Centre NHIR BRU, University of Nottingham, Nottingham, UK; <sup>2</sup>Neuro-gastroenterology and Motility, Wythenshawe Hospital, Manchester, UK

**Introduction** A proportion of patients with IBS-D describe frequent bowel movements first thing in the morning. While most clinicians recognise the phenomenon there is currently no definition of this "early morning rush" and no data describing the subgroup of patients who experience this disabling symptom which frequently impacts on their quality of life and ability to work.

Methods 119 patients meeting the Rome 3 criteria for IBS-D and 20 age and sex matched healthy volunteers (HV) completed a 1-week stool diary, hospital anxiety and depression score (HADS), and personal health questionnaire (PHQ-12). They also completed an IBS severity score (IBSSS) and IBS quality of life score (IBSQOL) as part of entry into a clinical trial. Whole gut transit (WGT) was measured during the placebo arm using the radio-opaque marker method. EMR was defined as  $\geq 2$  bowel movements within 1 h, between midnight and midday. Patients and HV were divided into 3 subgroups, those with  $\leq 2 \text{ days/week EMR} = \text{normal morning rush (NMR)}$ , those with 3-4 days/week EMR = moderate morning rush (MMR), and those with 5-7 days/week with EMR = severe morning rush (SMR). **Results** 16% of patients had MMR and 15% of patients had SMR. all HV had NMR. Those with SMR had greater psychological distress (sum of the HADS score) than those with NMR, 19.11  $(\pm 1.8)$  vs 13.48  $(\pm 0.8)$  p=0.021, and more somatic symptoms (PHQ-12), 9.2 (±0.9) vs 6.5 (±0.4) p=0.02. The SMR group had greater mean daily stool frequency than those with NMR and MMR 5.6 (3.5-8.2) vs 2.14 (1.7-3.0) and 3.7 (2.7-4.4) p<0.0001 with a higher IBSSS 366 (±18.4) vs 296.6 (±9.4) and 295.9 (±17.2) p=0.005, this was accompanied by a lower IBSQOL 334.3 (±21.1) vs 467.3 (±17.9) and 467.3 (±33.4) p=0.004. WGT (in hours) was significantly faster in the SMR group 7 (5.5-15) vs 19 (10-39) in the NMR and 16 (8.5-24.5) in the MMR groups p=0.03.

**Conclusion** Around 1/3 of IBS patients suffer from early morning rush. Those severely affected represent a group with a worse quality of life, greater psychological distress and more somatic symptoms. This is associated with faster whole gut transit and increased stool frequency. A third of the patients with SMR dropped out of the trial compared to <10% in the other groups making this a challenging subgroup to study.

Competing interests None declared.

## PWE-053 CYCLIC VOMITING SYNDROME IN 28 PATIENTS: DEMOGRAPHICS, FEATURES AND OUTCOMES

doi:10.1136/gutjnl-2012-302514d.53

<sup>1</sup>L Lee,\* <sup>1</sup>L Abbott, <sup>2</sup>J Burnett, <sup>3</sup>S Anderson, <sup>1</sup>S Moodie. <sup>1</sup>Department of Gastroenterology, Epsom and St Helier University Hospitals NHS Trust, London, UK; <sup>2</sup>Guy's and St Thomas' NHS Foundation Trust, London, UK; <sup>3</sup>Department of Gastroenterology, Guy's and St Thomas' NHS Foundation Trust, London, UK

**Introduction** Cyclic Vomiting syndrome (CVS) is a condition characterised by recurrent, stereotyped attacks of intense nausea and

intractable vomiting with no identifiable organic cause. The diagnosis of CVS has been helped by the Rome III diagnostic criteria, however, the condition is still a very heterogeneous group of symptoms and there have been very little studies analysing in detail patient-reported features. There is now some evidence for the role of tricyclic antidepressants in managing these patients, but as yet, there is no evidence on the long-term outcomes of patients treated conservatively.

**Methods** This was a retrospective cohort study of all patients treated at two London teaching hospitals. Information was gathered by means of inpatient case notes, clinic letters and telephone interviews with standardised questions.

**Results** 28 patients were identified, 17 with adult onset-CVS and 11 with childhood-onset CVS. Overall, 54.5% of patients noted that each attack occurred at the same time of day, usually between 4:00–6:00. In the adult-onset CVS cohort, the average age of onset was 30.9 years; the prevalence of headache was 57.1%. Vomiting attacks occurred on average 10 times a year with a mean duration of 55.3 h. In the childhood-onset CVS cohort, the average age of onset was 5.7 years and the prevalence of headaches was 44.4%. Vomiting attacks occurred on average 25.5 times a year with a mean duration of 54.5 h. During acute admissions patients rated morphine-based medications and ondansetron as most effective. Long-term, 65.4% of our patients were treated conservatively and of these 42.1% felt their symptoms had improved and a further 23.8% noted that their symptoms had resolved completely.

**Conclusion** Cyclic Vomiting Syndrome is a debilitating illness with a high impact on patient's quality of life. There is a high association with anxiety/depression as well as headaches. Morphine based medications are the most efficacious symptomatic acute treatment. Conservative management has a role to play in the long-term treatment of these patients. The prognosis of these patients is good with nearly 70% of patients having an improvement in their symptoms and nearly a quarter having resolution of the condition after 7 years.

### Abstract PWE-053 Table 1

	Overall	Adults	Children
No/year, mean (SD)	16.3 (22.9)	10.0 (12.1)	25.5 (31.4)
Duration, mean hours (SD)	55 (43.8)	55.3 (39.9)	54.5 (50.7)
Vomiting freq, mean (SD)	4.1 (2.6)	3.5 (1.7)	4.6 (3.3)
Duration of recovery phase, mean hours (SD)	53.2 (47)	59.1 (43.6)	45 (53.2)

Competing interests None declared.

# PWE-054 THE MANAGEMENT OF CYCLIC VOMITING SYNDROME: A SYSTEMATIC REVIEW OF 1141 CASES

#### doi:10.1136/gutjnl-2012-302514d.54

L Lee,\* L Abbott, B Mahlangu, S Moodie. *Epsom and St Helier University Hospitals NHS Trust, London, UK* 

**Introduction** Cyclic Vomiting syndrome (CVS) is characterised by recurrent attacks of intractable vomiting with no identifiable organic cause. It can take years before CVS is diagnosed, furthermore there have only been a handful of case studies looking at management strategies to reduce the duration/frequency or intensity of cyclic vomiting attacks. The objectives of this review were to identify associated clinical features that would help suggest a diagnosis of CVS and to review the literature to identify management strategies with the highest efficacy.

**Methods** A literature search was performed using the databases MEDLINE via Ovid (1948 to October 2011) and EMBASE (1980 to October 2011). The search terms included "Cyclic" and "Vomiting".